Peptide profile · Weight Management
Setmelanotide
Targeted MC4R agonist for rare genetic obesity caused by melanocortin pathway defects
Written & reviewed by Michael Carroll · Research, Peptide Initiative
Typical dose
3 mg
Half-life
~11 hours
Bioavailability
~79% subcutaneous bioavailability
Molecular weight
1,117.3 Da
Evidence level
Strong human trials
01 · Compound profile
Scientific & efficacy data
Molecular formula
C49H68N18O9S2
Primary benefits
Dramatic weight reduction (10-23%) in patients with rare genetic obesity by restoring MC4R-mediated satiety signaling that is absent due to upstream pathway mutations
Comprehensive metabolic improvement including BMI reduction, improved lipid profiles, and resolution of hyperphagia-driven metabolic dysfunction
Transformative reduction in insatiable hunger (hyperphagia) that characterizes monogenic obesity, dramatically improving daily functioning and psychosocial wellbeing
Rhythm Pharmaceuticals
Amino acid sequence
H-Nle4-D-Phe7-Arg8-Trp9-Lys10(Ac-γ-MSH-analogue)-NH202 · Dosing
How much do I take?
3 mg · once daily
Subcutaneous: A small injection into the fatty layer just under the skin — the same way insulin is given.
Bioavailability High — most of the dose reaches your bloodstream, just more gradually than an IV.
Best time to take
Administer Setmelanotide at the same time each day (or on the same day each week for weekly injections). Many users prefer morning or evening administration. Pick a time you'll remember consistently.
With food?
Setmelanotide injections can be given regardless of meal timing. However, if GI effects occur, administering on an empty stomach or with a light meal may help reduce discomfort.
If stacking
Setmelanotide should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.
＋ Increase if
- +You've tolerated the current dose for the recommended period without significant side effects
- +Therapeutic goals haven't been met at the current dose level
- +Your healthcare provider recommends dose escalation based on your response
- +Lab work or clinical assessments support a higher dose
－ Decrease if
- −Side effects are bothersome or impacting daily life despite management strategies
- −You experience any signs of an adverse reaction
- −Lab results indicate the need for dose reduction
- −Your healthcare provider recommends a lower dose based on your response
✓ Signs of right dose
- ✓Therapeutic goals being met with minimal side effects
- ✓Stable and consistent response to treatment
- ✓Lab values or clinical markers trending in the right direction
- ✓Good tolerance with manageable or absent side effects
Dosing Calculator
Calculate Your Exact Dose
Step 1: Peptide Weight
Find the weight printed on your peptide vial label
Look here!
The peptide weight is printed on the label
Look here!
The weight is on the label
Select Weight
Look for a number followed by 'mg' on the vial label (e.g., 5mg, 10mg)
03 · Suitability
Is this right for me?
Best for treating obesity caused by confirmed pomc deficiency mutations & managing obesity from pcsk1 or lepr genetic defects
Best for
Treating obesity caused by confirmed POMC deficiency mutations
Setmelanotide is particularly well-suited for individuals focused on treating obesity caused by confirmed pomc deficiency mutations. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Managing obesity from PCSK1 or LEPR genetic defects
Setmelanotide is particularly well-suited for individuals focused on managing obesity from pcsk1 or lepr genetic defects. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Reducing hyperphagia and body weight in Bardet-Biedl syndrome
Setmelanotide is particularly well-suited for individuals focused on reducing hyperphagia and body weight in bardet-biedl syndrome. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Addressing early-onset severe obesity with identified melanocortin pathway mutations
Setmelanotide is particularly well-suited for individuals focused on addressing early-onset severe obesity with identified melanocortin pathway mutations. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Consider alternatives if
Do not use if
Use with caution if
Not sure?
Compare Setmelanotide with similar peptides to find the best fit for your goals.
04 · Administration
How do I use it?
subcutaneous injection
Reconstitution — what you need
Example
Add the recommended volume of bacteriostatic water to the Setmelanotide vial. Gently swirl (do not shake) until the powder is fully dissolved. The resulting solution should be clear. Calculate your individual dose based on the concentration and your prescribed amount.
Your dose of Setmelanotide is determined by your healthcare provider. Using an insulin syringe marked in units, draw up the exact amount prescribed. For example, if the reconstituted concentration is 1mg/mL and your dose is 0.5mg, draw up 0.5mL (50 units on an insulin syringe). Always double-check calculations before injection.
Route
Subcutaneous injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training
Best sites
Technique
- 01Wash your hands thoroughly with soap and water before handling supplies
- 02Clean the injection site with an alcohol swab and let it air dry completely
- 03Pinch a fold of skin at the chosen injection site
- 04Insert the needle at a 45-90 degree angle (depending on needle length and body composition)
- 05Inject the medication slowly and steadily over 5-10 seconds
- 06Release the skin fold and remove the needle, applying gentle pressure with a clean swab
- 07Rotate injection sites to prevent tissue irritation or lipodystrophy
- 08Dispose of the needle safely in a sharps container—never recap or reuse needles
Storage · before reconstitution
Store Setmelanotide in the refrigerator at 36-46°F (2-8°C) in its original packaging. Protect from light and moisture. Do not freeze. Check the expiration date before use. Some formulations may be stored at room temperature for limited periods—check your specific product labeling.
Storage · after reconstitution
Once reconstituted, Setmelanotide should be kept refrigerated at 36-46°F (2-8°C) and used within the timeframe specified on your product labeling (typically 14-28 days). Label the vial with the reconstitution date. Do not use if the solution appears cloudy, discolored, or contains particles.
Signs of degradation
Sample daily schedule
05 · Safety
Is it safe?
4 common side effects · 2 serious
Setmelanotide demonstrates favorable tolerability in Phase 3 trials with safety data from over 200 patients across POMC, PCSK1, LEPR-deficient, and Bardet-Biedl syndrome populations. The most common adverse effect is dose-dependent skin hyperpigmentation (>60% of patients) due to off-target MC1R activation on melanocytes—a manageable, reversible pharmacological effect rather than true toxicity. Serious psychiatric adverse events including depression and suicidal ideation require baseline mental health screening and ongoing monitoring in all patients.
Safety evidence comes from Phase 3 trials (IMCIVREE, VENTURE) in pediatric and adult populations with confirmed genetic melanocortin pathway defects, with long-term follow-up data supporting chronic administration. FDA approval in 2020 and EMA approval in 2021 validate the benefit-risk profile in eligible populations. Ongoing Phase 2 studies in hypothalamic obesity, Prader-Willi syndrome, and Alström syndrome continue to characterize safety in expanded indications.
Common side effects · experienced by some users
Less common
These typically resolve with continued use or dose adjustment.
Stop and seek help if
- ×Severe or worsening side effects that don't improve with dose adjustment or supportive care
- ×Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
- ×Your healthcare provider recommends discontinuation based on your clinical response
- ×Development of any new medical condition that may be contraindicated with Setmelanotide
- ×Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
- ×Abnormal lab results or clinical markers that suggest adverse effects
Setmelanotide should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
With other peptides
- ✓Genetic Counseling — Essential for confirming melanocortin pathway mutations and identifying eligible patients for targeted MC4R agonist therapy
- ✓Behavioral Therapy — Complementary approach to support dietary and lifestyle modifications alongside pharmacological hunger reduction
- ✓Nutritional Counseling — Supports healthy eating patterns as hyperphagia resolves and appetite normalizes with treatment
With medications
- !Other MC4R Agonists — Redundant mechanism of action with increased risk of melanocortin-related side effects including excessive hyperpigmentation
- !Medications Affecting Melanocortin Signaling — Potential unpredictable interactions with melanocortin pathway signaling and altered efficacy or safety profile
- !Photosensitizing Agents — May exacerbate skin pigmentation changes and increase risk of melanocytic nevus development in the setting of MC1R activation
With supplements
- ✓Multivitamins — Generally safe to take alongside Setmelanotide. Space doses apart if taking oral formulations to ensure optimal absorption.
- ✓Electrolyte supplements — Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.
06 · Effectiveness
How do I know it's working?
Strong human trials · first signs weeks 1-4
Evidence level
Strong human trials
(Phase 3 or FDA approved)
How it works
Setmelanotide is a brain hormone activator that works like a master switch for appetite control. In people with rare genetic defects, this appetite switch gets stuck in the 'on' position, causing extreme hunger and obesity from childhood. Setmelanotide turns that switch back off by activating the melanocortin-4 receptor in the brain, telling your body to eat less and feel satisfied with smaller meals.
Setmelanotide (RM-493) is a potent, selective agonist of the melanocortin-4 receptor (MC4R), a G-protein coupled receptor expressed predominantly in the paraventricular and dorsomedial hypothalamus. MC4R activation is critical for appetite suppression and energy expenditure in the leptin-melanocortin signaling pathway. Setmelanotide directly activates MC4R downstream of POMC neurons, bypassing upstream defects in leptin signaling (LEPR), POMC synthesis (POMC, PCSK1), or leptin signaling intermediates, thereby restoring physiologic appetite suppression in patients with monogenic obesity. The drug's EC50 for human MC4R is approximately 0.2 nM, making it highly selective and potent. By activating MC4R on pro-opiomelanocortin (POMC) neurons and other appetite-regulating circuits, setmelanotide reduces hyperphagia, increases satiety, and promotes weight loss specifically in patients with POMC, PCSK1, or LEPR deficiency—conditions that cause severe, treatment-resistant obesity due to leptin-melanocortin pathway dysfunction.
What to expect
Weeks 1-4
What you might notice
- •Beginning of dose titration from 0
- •5-1 mg
- •Possible early reduction in hunger intensity
- •Mild injection site reactions
- •Early signs of skin darkening may begin
What's normal
- •Appetite changes may be subtle initially during low-dose titration
- •Skin hyperpigmentation develops gradually
- •Mild nausea or GI changes are common and usually transient
What's next
- →Continue dose titration by 0
- →5 mg every 2 weeks
- →Monitor body weight, hunger scores, and skin changes
- →Target maintenance dose of 2-3 mg
Weeks 4-12
What you might notice
- •Meaningful reduction in hyperphagia as dose approaches maintenance level
- •Measurable weight loss beginning
- •Skin hyperpigmentation becoming more apparent
What's normal
- •Hunger reduction is typically the earliest noticeable clinical effect
- •Weight loss follows as caloric intake decreases
- •Skin darkening continues to develop and is an expected pharmacological effect
What's next
- →Achieve maintenance dose (2-3 mg)
- →Assess clinical response with weight measurements and hyperphagia questionnaires
- →Begin regular dermatological monitoring
Weeks 12-52
What you might notice
- •Sustained weight loss with many patients achieving >10% body weight reduction
- •Significant and sustained hyperphagia reduction
- •Stable skin pigmentation
What's normal
- •Weight loss trajectory may vary between genetic subtypes (POMC/PCSK1 patients tend to respond more robustly than LEPR or BBS)
- •Hunger suppression is typically well-maintained
- •Skin changes stabilize
What's next
- →Continue chronic maintenance therapy
- →Reassess every 3-6 months
- →If <5% weight loss after adequate trial at maximum dose, consider whether to continue
- →Long-term treatment required as weight regain occurs upon discontinuation
Signs it's working · Treatment Response
- ✓Improvement in the primary symptoms or condition being treated
- ✓Positive changes in relevant lab values or clinical markers
- ✓Consistent, stable response to Setmelanotide over time
- ✓Reduction in symptom frequency or severity
Signs it's working · General Well-being
- ✓Improved energy levels and daily functioning
- ✓Better quality of life related to the treated condition
- ✓Manageable or absent side effects indicating good tolerance
- ✓Positive feedback from healthcare provider during check-ups
Not seeing results? Common reasons
- •Not at therapeutic dose yet—initial doses are for building tolerance, not maximum effect
- •Insufficient time at target dose—most compounds need several weeks to show full benefits
- •Inconsistent dosing schedule—regular, consistent use is crucial for optimal results
- •Individual variation in response—genetics, metabolism, and other factors affect outcomes
- •Underlying conditions or medications interfering with absorption or effectiveness
- •Improper storage leading to degraded product—always verify proper storage conditions
Key research
07 · Questions
Frequently asked
Who is eligible for setmelanotide treatment?+
Setmelanotide is specifically approved for patients aged 6 years and older with obesity caused by genetically confirmed POMC (proopiomelanocortin) deficiency, PCSK1 (proprotein convertase subtilisin/kexin type 1) deficiency, LEPR (leptin receptor) deficiency, or Bardet-Biedl syndrome. Genetic testing to confirm one of these conditions is required before starting treatment. It is not approved for common (polygenic) obesity.
Why does setmelanotide cause skin darkening?+
Setmelanotide activates MC4R to reduce appetite, but it also has some activity at MC1R (melanocortin-1 receptor) on skin melanocytes. MC1R activation stimulates melanin production, leading to skin hyperpigmentation. This is similar to how alpha-MSH (the natural ligand) causes tanning. While setmelanotide has ~20-fold selectivity for MC4R over MC1R, the MC1R effect is sufficient to cause noticeable skin darkening in most patients.
What happens if treatment is stopped?+
Setmelanotide addresses the symptom (hyperphagia and obesity) but does not correct the underlying genetic defect. If treatment is discontinued, hyperphagia and weight regain are expected to return as MC4R is no longer being directly stimulated. Long-term, continuous treatment is generally necessary to maintain the benefit.
How is setmelanotide different from GLP-1 receptor agonists like semaglutide?+
Setmelanotide works through an entirely different mechanism — it targets the melanocortin-4 receptor (MC4R) in the hypothalamus, which is specific to the leptin-melanocortin appetite pathway. GLP-1 agonists like semaglutide work through the incretin system affecting insulin, glucagon, and gastric emptying. Setmelanotide is uniquely effective in patients with genetic defects in the melanocortin pathway where GLP-1 agonists may be less effective, because the fundamental problem is a disruption in MC4R-mediated satiety signaling.
Can setmelanotide be used in children?+
Yes, setmelanotide is approved for patients aged 6 years and older with qualifying genetic obesity conditions. The VENTURE trial specifically studied children aged 2-5 years, showing 83% achieved meaningful BMI reduction with a favorable safety profile. Pediatric dosing starts at 0.5 mg once daily with careful titration.
Is genetic testing required before starting setmelanotide?+
Yes, genetic testing confirming POMC, PCSK1, or LEPR deficiency or Bardet-Biedl syndrome is required before treatment. Setmelanotide works by bypassing upstream genetic defects in the melanocortin pathway, so it is only effective when these specific mutations are present. Rhythm Pharmaceuticals offers a free genetic testing program (Uncovering Rare Obesity) to help identify eligible patients.
08 · Further reading
History & related research
History · since 2006
The Drug That Finally Fixed the Broken Hunger Switch
A child born with POMC deficiency doesn't just get hungry — their brain never receives the 'stop eating' signal. They can weigh 300 pounds by age ten despite parents' desperate efforts to limit food.
Read the full history of Setmelanotide